Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Eukaryotic translation initiation factor 4E (eIF4E)

In vitro studies have identified an inhibitor of eIF4E that could help treat cancer. A derivative of a tricyclic 2-(4-(3,4-dichlorophenyl)thiazol-2-yl) was synthesized that was threefold more potent in competitive binding to eIF4E than the parent compound. In a human melanoma cell line, the new compound inhibited proliferation with an IC50 of 5.1 mM. Next steps include further optimization of structural and functional aspects of the eIF4E inhibitor.

SciBX 7(24); doi:10.1038/scibx.2014.700
Published online June 19, 2014

Patent application filed by Harvard University; licensed to a private entity; available for partnering

Mahalingam, P. et al. J. Med. Chem.;
published online May 14, 2014;
doi:10.1021/jm401733v
Contact: Michael Chorev, Brigham and Women's Hospital, Boston, Mass.
e-mail:
michael_chorev@hms.harvard.edu